Preview Mode Links will not work in preview mode

Jul 11, 2019

Proceedings from a CME symposium held at the 2019 ASCO Annual Meeting. Featuring perspectives from Prof Dirk Arnold and Drs Tanios Bekaii-Saab, Joseph Chao, Anthony El-Khoueiry, Richard S Finn, Yelena Y Janjigian, Scott Kopetz and Eileen M O’Reilly.

  • Introduction (00:00)
  • Program overview: Dr Love
  • Hepatocellular Carcinoma (HCC) — Dr El-Khoueiry and Dr Finn (2:01)
  • Case (Dr Gujja): A man in his mid-70s with Child-Pugh A multifocal HCC and a tumor thrombus in the midhepatic vein extending into the floor of the right atrium (2:12)
  • Case (Dr Park): A woman in her early 70s with Child-Pugh B HCC who developed hand-foot syndrome and required a dose reduction while receiving first-line sorafenib and now has progressive disease (16:11)
  • Pancreatic Adenocarcinoma (PAD) — Dr Bekaii-Saab and Dr O’Reilly (41:01)
  • Case (Dr Ibrahim): A man in his late 50s with symptomatic metastatic PAD who experienced a dramatic response to modified FOLFIRINOX (52:14)
  • Cases (Dr Park and Dr Morganstein): Elderly patients with metastatic PAD, poor performance status and disease progression on nab paclitaxel/gemcitabine (1:00:22)
  • Case (Dr Gujja): A woman in her late 60s with metastatic PAD and a germline BRCA2 mutation (1:06:00)
  • Gastric/Gastroesophageal (GEJ) Cancers — Dr Chao and Dr Janjigian (1:20:30)
  • Case (Dr Favaro): A man in his late 30s with HER2-positive metastatic gastric cancer who received paclitaxel/ramucirumab after disease progression and worsening neuropathy on FOLFOX/trastuzumab (1:35:52)
  • Case (Dr Morganstein): A man in his mid-60s with microsatellite-stable, PD-L1-negative metastatic GEJ cancer who attained a complete response to second-line nivolumab (1:39:34)
  • Colorectal Cancer (CRC) — Prof Arnold and Dr Kopetz (1:52:56)
  • Case (Dr Morganstein): A woman in her early 40s with widespread RAS wild-type, microsatellite-stable, left-sided metastatic CRC (mCRC) (1:57:43)
  • Case (Dr Ibrahim): A woman in her late 70s with MSI-high mCRC who refused chemotherapy and experienced a completed response to pembrolizumab (2:04:01)
  • Case (Dr Favaro): A woman in her late 80s with RAS wild-type, microsatellite-stable, right-sided mCRC with a BRAF V600E tumor mutation who received BRAF-targeted therapy (2:13:49)

Select publications